S&P Futures
3,848.75 +0.50 (+0.01%) Dow Futures
31,017.00 +4.00 (+0.01%) Nasdaq Futures
11,884.00 +3.75 (+0.03%) Russell 2000 Futures
1,728.20 -0.40 (-0.02%) Crude Oil
98.37 -0.16 (-0.16%) Gold
1,737.80 +1.30 (+0.07%)
Nutra Pharma Corp. (NPHC)
Chart Events
Performance Outlook
| Previous Close | 0.0009 |
| Open | 0.0009 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0007 - 0.0015 |
| 52 Week Range | 0.0002 - 0.0087 |
| Volume | |
| Avg. Volume | 730,788 |
| Market Cap | 10.989M |
| Beta (5Y Monthly) | 2.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0020 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Nutra Pharma Announces First Manufacturing Agreement
Nutra Pharma is announcing Avini Health as its first contract manufacturing partnerPlantation, Florida, March 23, 2022 (GLOBE NEWSWIRE) -- Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Equine Pain-Away™ and Luxury Feet™ in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, is announcing their first agreement to act as a product
- GlobeNewswire
Nutra Pharma Expands Manufacturing Capabilities
Nutra Pharma is providing updates on their work in improving manufacturing scale and capabilities for new product launches for their OTC drugs and potential dietary supplementsPlantation, Florida, March 17, 2022 (GLOBE NEWSWIRE) -- Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Equine Pain-Away™ and Luxury Feet™ in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Im
- GlobeNewswire
Nutra Pharma Letter to Shareholders
Nutra Pharma has published their annual letter to shareholders to the Company’s websitePlantation, Florida, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Luxury Feet™ and Equine Pain-Away™ in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, announced today that the Company's Chief Executive Of
